HAMILTON, Ontario (MedPage Today) -- The experimental monoclonal antibody mepolizumab (Bosatria) may reduce corticosteroid requirements and exacerbations in patients with severe refractory asthma.
Investigational Biologic Agent May Reduce Severe Asthma Exacerba...Courtesy MedPage Today Allergy & Immunology Wed, 03/04/2009 - 15:00
HAMILTON, Ontario (MedPage Today) -- The experimental monoclonal antibody mepolizumab (Bosatria) may reduce corticosteroid requirements and exacerbations in patients with severe refractory asthma. More related itemsTraffic-Related Asthma Costs Underestimated (CME/CE)
Early Infant Weight Gain Tied to Asthma (CME/CE)
Mobile Asthma Clinic of Little Benefit to Kids...
Finger Pulse Oximeter Octive Tech 300C with Hard...
Burt's Bees - Baby Bee Buttermilk Lotion, 7 fl oz...
|
Popular by tags WeekMonth |
Post new comment